Anterior Uveitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major anterior uveitis markets reached a value of US$ 195.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 316.0 Million by 2034, exhibiting a growth rate (CAGR) of 4.45% during 2024-2034.
The anterior uveitis market has been comprehensively analyzed in IMARC's new report titled "Anterior Uveitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Anterior uveitis, also known as iritis, refers to an inflammatory condition that affects the front portion of the uvea, the middle membrane of the eye. This illness typically involves inflammation of the iris, the colored part of the eye surrounding the pupil. The symptoms of the ailment may include eye redness, sensitivity to light (photophobia), blurred vision, and pain or discomfort. Patients might also experience increased tearing and a feeling of something in the eye. These signs can vary in severity and may develop suddenly. The diagnosis of anterior uveitis involves a comprehensive eye examination by an ophthalmologist. The physicians will assess the patient's medical history and indications, conduct a visual acuity test, and carefully examine the eye using a slit lamp microscope. Pupil dilation is often performed to allow a better view of the structures within the eye. Additionally, numerous diagnostic tests, such as blood workups and imaging studies, are recommended to determine the underlying cause of the inflammation.
The increasing cases of systemic diseases, such as rheumatoid arthritis and ankylosing spondylitis, are primarily driving the anterior uveitis market. In addition to this, the inflating utilization of effective medications, including corticosteroids, immunosuppressive drugs, and biologics, for managing inflammation and preventing ocular complications is also creating a positive outlook for the market. Moreover, the widespread adoption of advanced diagnostic techniques like optical coherence tomography (OCT) and anterior chamber paracentesis for accurate and timely diagnosis of the ailment is further bolstering the market growth. These technologies aid in precise visualization of the affected intraocular structures and facilitate appropriate therapeutic interventions. Apart from this, the rising application of personalized treatment approaches, tailoring the therapeutic regimen based on the specific etiology and severity of anterior uveitis, is acting as another significant growth-inducing factor. Additionally, the escalating demand for surgical interventions, such as vitrectomy and implantation of sustained-release drug delivery systems, which offer enhanced control over disease progression and better preservation of visual function, is also augmenting the market growth. Furthermore, the emerging popularity of regenerative therapies and stem cell techniques to help in restoring ocular tissue integrity and suppressing inflammation is expected to drive the anterior uveitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the anterior uveitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for anterior uveitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the anterior uveitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the anterior uveitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the anterior uveitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current anterior uveitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the anterior uveitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the anterior uveitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the anterior uveitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of anterior uveitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of anterior uveitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of anterior uveitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with anterior uveitis across the seven major markets?
What is the size of the anterior uveitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of anterior uveitis?
What will be the growth rate of patients across the seven major markets?
Anterior Uveitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for anterior uveitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the anterior uveitis market?
What are the key regulatory events related to the anterior uveitis market?
What is the structure of clinical trial landscape by status related to the anterior uveitis market?
What is the structure of clinical trial landscape by phase related to the anterior uveitis market?
What is the structure of clinical trial landscape by route of administration related to the anterior uveitis market?
The anterior uveitis market has been comprehensively analyzed in IMARC's new report titled "Anterior Uveitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Anterior uveitis, also known as iritis, refers to an inflammatory condition that affects the front portion of the uvea, the middle membrane of the eye. This illness typically involves inflammation of the iris, the colored part of the eye surrounding the pupil. The symptoms of the ailment may include eye redness, sensitivity to light (photophobia), blurred vision, and pain or discomfort. Patients might also experience increased tearing and a feeling of something in the eye. These signs can vary in severity and may develop suddenly. The diagnosis of anterior uveitis involves a comprehensive eye examination by an ophthalmologist. The physicians will assess the patient's medical history and indications, conduct a visual acuity test, and carefully examine the eye using a slit lamp microscope. Pupil dilation is often performed to allow a better view of the structures within the eye. Additionally, numerous diagnostic tests, such as blood workups and imaging studies, are recommended to determine the underlying cause of the inflammation.
The increasing cases of systemic diseases, such as rheumatoid arthritis and ankylosing spondylitis, are primarily driving the anterior uveitis market. In addition to this, the inflating utilization of effective medications, including corticosteroids, immunosuppressive drugs, and biologics, for managing inflammation and preventing ocular complications is also creating a positive outlook for the market. Moreover, the widespread adoption of advanced diagnostic techniques like optical coherence tomography (OCT) and anterior chamber paracentesis for accurate and timely diagnosis of the ailment is further bolstering the market growth. These technologies aid in precise visualization of the affected intraocular structures and facilitate appropriate therapeutic interventions. Apart from this, the rising application of personalized treatment approaches, tailoring the therapeutic regimen based on the specific etiology and severity of anterior uveitis, is acting as another significant growth-inducing factor. Additionally, the escalating demand for surgical interventions, such as vitrectomy and implantation of sustained-release drug delivery systems, which offer enhanced control over disease progression and better preservation of visual function, is also augmenting the market growth. Furthermore, the emerging popularity of regenerative therapies and stem cell techniques to help in restoring ocular tissue integrity and suppressing inflammation is expected to drive the anterior uveitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the anterior uveitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for anterior uveitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the anterior uveitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the anterior uveitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the anterior uveitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current anterior uveitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the anterior uveitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the anterior uveitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the anterior uveitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of anterior uveitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of anterior uveitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of anterior uveitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with anterior uveitis across the seven major markets?
What is the size of the anterior uveitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of anterior uveitis?
What will be the growth rate of patients across the seven major markets?
Anterior Uveitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for anterior uveitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the anterior uveitis market?
What are the key regulatory events related to the anterior uveitis market?
What is the structure of clinical trial landscape by status related to the anterior uveitis market?
What is the structure of clinical trial landscape by phase related to the anterior uveitis market?
What is the structure of clinical trial landscape by route of administration related to the anterior uveitis market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ANTERIOR UVEITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ANTERIOR UVEITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ANTERIOR UVEITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ANTERIOR UVEITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ANTERIOR UVEITIS - UNMET NEEDS
10 ANTERIOR UVEITIS - KEY ENDPOINTS OF TREATMENT
11 ANTERIOR UVEITIS - MARKETED PRODUCTS
11.1 List of Anterior Uveitis Marketed Drugs Across the Top 7 Markets
11.1.1 Durezol (Difluprednate ophthalmic) - Novartis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ANTERIOR UVEITIS - PIPELINE DRUGS
12.1 List of Anterior Uveitis Pipeline Drugs Across the Top 7 Markets
12.1.1 TRS01 - Tarsier Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 ANTERIOR UVEITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 ANTERIOR UVEITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ANTERIOR UVEITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Anterior Uveitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Anterior Uveitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Anterior Uveitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Anterior Uveitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Anterior Uveitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Anterior Uveitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Anterior Uveitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Anterior Uveitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Anterior Uveitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Anterior Uveitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Anterior Uveitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Anterior Uveitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Anterior Uveitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Anterior Uveitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Anterior Uveitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Anterior Uveitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Anterior Uveitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Anterior Uveitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Anterior Uveitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Anterior Uveitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Anterior Uveitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Anterior Uveitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Anterior Uveitis - Access and Reimbursement Overview
16 ANTERIOR UVEITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ANTERIOR UVEITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ANTERIOR UVEITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ANTERIOR UVEITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ANTERIOR UVEITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ANTERIOR UVEITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ANTERIOR UVEITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ANTERIOR UVEITIS - UNMET NEEDS
10 ANTERIOR UVEITIS - KEY ENDPOINTS OF TREATMENT
11 ANTERIOR UVEITIS - MARKETED PRODUCTS
11.1 List of Anterior Uveitis Marketed Drugs Across the Top 7 Markets
11.1.1 Durezol (Difluprednate ophthalmic) - Novartis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ANTERIOR UVEITIS - PIPELINE DRUGS
12.1 List of Anterior Uveitis Pipeline Drugs Across the Top 7 Markets
12.1.1 TRS01 - Tarsier Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 ANTERIOR UVEITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 ANTERIOR UVEITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ANTERIOR UVEITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Anterior Uveitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Anterior Uveitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Anterior Uveitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Anterior Uveitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Anterior Uveitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Anterior Uveitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Anterior Uveitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Anterior Uveitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Anterior Uveitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Anterior Uveitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Anterior Uveitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Anterior Uveitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Anterior Uveitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Anterior Uveitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Anterior Uveitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Anterior Uveitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Anterior Uveitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Anterior Uveitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Anterior Uveitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Anterior Uveitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Anterior Uveitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Anterior Uveitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Anterior Uveitis - Access and Reimbursement Overview
16 ANTERIOR UVEITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ANTERIOR UVEITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ANTERIOR UVEITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
